Cleveland BioLabs, Inc.Find Ratings Reports
CLEVELAND BIOLABS INC's gross profit margin for the third quarter of its fiscal year 2020 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its subsector. CLEVELAND BIOLABS INC is extremely liquid. Currently, the Quick Ratio is 6.55 which clearly shows the ability to cover any short-term cash needs. CBLI managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 33.83% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY20||Q3 FY19|
|Net Sales ($mil)||0.04||0.27|
|Net Income ($mil)||-0.75||-0.45|
|Balance Sheet||Q3 FY20||Q3 FY19|
|Cash & Equiv. ($mil)||3.04||1.91|
|Total Assets ($mil)||3.23||2.23|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q3 FY20||Q3 FY19|
|Gross Profit Margin||-1750.0||-191.11|
|Return on Assets||-74.62||-106.41|
|Return on Equity||0.0||0.0|
|Debt||Q3 FY20||Q3 FY19|
|Share Data||Q3 FY20||Q3 FY19|
|Shares outstanding (mil)||13.02||11.3|
|Div / share||0.0||0.0|
|Book value / share||-0.17||-0.3|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2768689.0||207870.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the subsector average.
|CBLI NM||Peers 33.50||CBLI NM||Peers 102.28|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CBLI's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CBLI's P/CF is negative making the measure meaningless.
|CBLI NA||Peers 21.30||CBLI NA||Peers 0.70|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CBLI NM||Peers 11.72||CBLI 4.77||Peers 5.00|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CBLI's P/B is negative making this valuation measure meaningless.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CBLI is expected to keep pace with its peers on the basis of earnings growth.
|CBLI 75.41||Peers 1929.85||CBLI -35.68||Peers 699.03|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CBLI is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
CBLI significantly trails its peers on the basis of sales growth.